Willow vs IVIM Health: Tracking and support vs ratings and pricing

Willow vs IVIM Health pits a telehealth-first, progress-tracking program against a high-rated compounded-GLP-1 platform with promotional pricing. Early verdict: choose Willow if you prioritize structured digital follow-up and behavioral support; choose IVIM Health if you prioritize third-party ratings, lower starting cost, and IVIM’s proprietary optimization protocol.

Explore Willow’s progress tracking and follow-up

How they differ at a glance

This comparison focuses on four distinctive differences supported by the sources: pricing and promotional offers, support and program model, compounded medication and regulatory notes, and third-party ratings and outcome claims. Each section directly compares Willow and IVIM Health using only the captured evidence.

Pricing and promotional offers

IVIM Health reports a lower entry price and explicit promotional options: starting price materials list $75/mo for semaglutide, $133/mo for tirzepatide, plus a $74.99/mo program fee and promotional codes including a free month with code GIFT75. IVIM’s FAQ also notes a $99 first month and $174/month ongoing in other captured statements. Willow’s captured evidence shows a starting price of 299 and a price detail of 299. No other verified shipping, membership, cancellation, or fee details for Willow were captured.

See IVIM Health’s pricing and free month code

Support, program model, and ongoing follow-up

Willow is presented as a telehealth-first weight management program that emphasizes structured progress tracking and follow-up consultations. The source frames Willow as converting GLP-1 efficacy into longer term outcomes through behavioral scaffolding and a licensed telehealth team. IVIM Health is described as a licensed telehealth platform with a clinician-guided GLP-1 ID protocol that includes weekly dose adjustments and a structured optimization approach. IVIM markets a no-obligation free consultation valued at $75 for new patients.

Compare Willow’s follow-up and licensed telehealth team

Compounded medications and regulatory notes

Both sources include regulatory qualifiers about compounded drugs. Willow’s captured material states that compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. IVIM Health’s materials repeatedly state its compounded medications are not FDA-approved, have not been reviewed by the FDA for safety, effectiveness or quality, and that compounded products carry risks and are not appropriate for everyone. IVIM notes compounded medications are prepared by independent licensed compounding pharmacies and are prescribed only after consultation with an Ivím provider.

Third-party ratings and outcome claims

IVIM Health highlights a dual 4.9-star rating on Google and Trustpilot, described as an unusually strong satisfaction signal. IVIM also presents a proprietary protocol claim that patients following the Ivim Protocol lost an average of 46% more weight over 68 weeks compared to another published clinical GLP-1 trial, and a claim that GLP-1 ID can accelerate weight loss by up to 40%. These outcome statements are described in the source as not a head-to-head study and as IVIM’s own protocol claims. Willow’s captured assets emphasize program structure and follow-up rather than third-party rating metrics or specific outcome percentages. No independent third-party rating for Willow was captured.

Comparison table

Criteria	Willow	IVIM Health
Starting price	299 (captured)	$75/mo listed; other materials show $99 first month and $174/month ongoing; GIFT75 free month code
Program focus	Oral GLP-1 with progress tracking and follow-up support	Clinician-guided GLP-1 ID protocol with weekly adjustments and membership options
Support model	Licensed telehealth team, follow-up consultations, progress tracking tools	Licensed telehealth clinicians, no-obligation free consult ($75 value), program fee applies
Compounded medication note	Compounded medications, when offered, are not FDA-approved and not reviewed by FDA	Compounded drugs are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality
Third-party validation	No third-party rating captured	4.9-star rating on both Google and Trustpilot; proprietary outcome claims described with qualifiers

Practical differences that matter

If upfront cost and third-party ratings are top priorities, IVIM Health’s lower reported starting price appearances, free-month code, and dual 4.9-star ratings offer a clear appeal. If structured digital follow-up and an emphasis on behavioral support matter more, Willow positions itself as a program that pairs oral GLP-1 with progress tracking and follow-up consultations provided by a licensed telehealth team. Both providers emphasize clinician review and include regulatory language that compounded products are not FDA-approved.

Check IVIM Health’s protocol and reviews

Conclusion: Willow vs IVIM Health

Willow vs IVIM Health reduces to support model versus pricing and third-party validation. Willow centers on structured digital follow-up and progress tracking together with a licensed telehealth team. IVIM Health centers on lower advertised entry pricing options, a free consultation, dual 4.9-star third-party ratings, and a proprietary GLP-1 ID optimization protocol. Both note compounded medications are not FDA-approved and require clinician evaluation.

Choose Willow if you want a telehealth-first program focused on progress tracking, licensed clinician follow-up, and structured behavioral support. Choose IVIM Health if you value lower starting-price options, a free consultation for new patients, strong third-party ratings, and IVIM’s clinician-guided optimization protocol.

Start with Willow’s structured program